

immediate release form.

64. (new) A dual release formulation for oral administration as claimed in claim 52, having a first portion comprising a sustained release formulation comprising sildenafil citrate and a second portion comprising sildenafil citrate in immediate release form.

65. (new) A dual-release formulation for oral administration as claimed in claim 52, having a first portion comprising a controlled release formulation comprising sildenafil or a pharmaceutically acceptable salt thereof and a second portion comprising sildenafil or a pharmaceutically acceptable salt thereof in immediate release form, wherein a multiplicity of coated cores is present in the first portion.

66. (new) A dual-release formulation for oral administration as claimed in claim 52, having a first portion comprising a controlled release formulation comprising sildenafil citrate and a second portion comprising sildenafil citrate in immediate release form, wherein a multiplicity of coated cores is present in the first portion.

REMARKS

Claims 31 through 53 are currently in the application, and stand allowed. These claims have been reproduced above for the sake of completeness.

By this amendment, new claims 54 through 66 have been added. All of the newly added claims are dependent from claims that were previously allowed.

In the newly added claims, Applicants have claimed additional preferred embodiments.

Claims 54, 56, 59, 61, 63, and 65 state that the cGMP PDE-5 inhibitor(s) is sildenafil or a pharmaceutically acceptable salt thereof. Support is in the specification at page 6, lines 13-14.

Claims 55, 57, 60, 62, 64, and 66 specify that the cGMP PDE-5 inhibitor is sildenafil citrate, as supported at page 6, line 14.

Claim 58 claims a formulation as claimed in claim 34, which is a sustained release formulation. Support is in the specification at page 3, line 14.

Claims 65 and 66 claim a dual release formulation as claim d in (allowed) claim 52. The claims additionally refer to the first portion of the dual release formulation as containing "a multiplicity of coated cores". Support is in the specification at page 8, lines 25-30.

It is respectfully submitted that new claims 54-66 are allowable for the reason that each depends from an already-allowed claim and each is supported by the specification. No further issues are seen, and a Notice of allowance is respectfully requested.

Authorization to charge fees for adding new claims

Thirteen (13) new claims have been added, all of them dependent. The fee for adding these new claims is accordingly $13 \times 18 = \$234.00$. The sum of \$234.00 should accordingly be charged to Deposit Account Number 16-1445 to cover the aforementioned claim fees.

Respectfully submitted,

Date: July 9, 2003


James T. Jones
Attorney for Applicant
Reg. No. 30,561

Pfizer Inc
Patent Department
Eastern Point Road
Groton, CT 06340
(860) 441-4903